How many drugs treat Hypoparathyroidism?

Drug Landscape tracks 8 marketed treatments for Hypoparathyroidism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypoparathyroidism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypoparathyroidism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypoparathyroidism (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypoparathyroidism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Yorvipath	PALOPEGTERIPARATIDE	Ascendis Pharma Bone		parathyroid hormone 1 receptor (PTH1R)	2025-01-01
Infuvite Adult	Colecalciferol	Novartis	Vitamin D	Vitamin D3 receptor	2000-01-01
Calcijex	CALCITRIOL	Esjay Pharma	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
Rocaltrol	Rocaltrol	Shandong University		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein
Hornel	FALECALCITRIOL	Taisho Pharmaceutical
Alphacalcidol	Alphacalcidol	University of Ioannina		Sodium-dependent noradrenaline transporter, Vitamin D3 receptor
Calciferol	Calciferol	Department of Medical Services Ministry of Public Health of Thailand		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Hypoparathyroidism
Esjay Pharma · 2 drugs in Hypoparathyroidism
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Hypoparathyroidism
Novartis · 1 drug in Hypoparathyroidism
Shandong University · 1 drug in Hypoparathyroidism
Taisho Pharmaceutical · 1 drug in Hypoparathyroidism
University of Ioannina · 1 drug in Hypoparathyroidism
Ascendis Pharma Bone · 1 drug in Hypoparathyroidism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypoparathyroidism:

Cite this brief

Drug Landscape (2026). Hypoparathyroidism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypoparathyroidism. Accessed 2026-06-10.

Hypoparathyroidism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing